ACTEG (@ACTEG_) profile picture

ACTEG

@ACTEG_

Compte oficial de l’ASSOCIACIÓ CATALANA DE TUMORS ESOFAGOGÀSTRICS

Joined November 2024
  • Tweets58
  • Following95
  • Followers60
36Media
Photo by ACTEG (@ACTEG_)Photo by ACTEG (@ACTEG_)Photo by ACTEG (@ACTEG_)Photo by ACTEG (@ACTEG_)Photo by ACTEG (@ACTEG_)Photo by ACTEG (@ACTEG_)Photo by ACTEG (@ACTEG_)Photo by ACTEG (@ACTEG_)Photo by ACTEG (@ACTEG_)Photo by ACTEG (@ACTEG_)
Editorial on ESOPEC 🇩🇪: 📊 FLOT vs CROSS in resectable esophageal/GEJ ADC
🧬 FLOT → ↑OS (66 vs 37 mo) & 3y RFS (54.5% vs 39%)
⚕️ Similar locoregional control, ↓ distant relapse (31.5% vs 47.2%)
🧫 Calls for biomarkers & periop ICI (e.g. D-FLOT) to refine curative strategies 🔗 ascopubs.org/doi/10.1200/JCO…
Image from Nieves Martinez Lago MD PhD (@DraMartinezLago)
1
50
148
7,288
❓Is esophagectomy always necessary in LA esophageal/GEJ cancer? ⚠️ Surgery = high morbidity/mortality, impaired QoL 📊 SANO: surveillance after cCR noninferior OS 🧪 IO & biomarkers may expand NOM 🚨 Ongoing trials (NEEDS/ESORES/SANO-2) could redefine standards 🔗 doi.org/10.1200/JCO-25-01197
Image from Nieves Martinez Lago MD PhD (@DraMartinezLago)
9
1
25
1,261
🟤Nivo-Ipi for 1L treatment of MSI-H advanced gastric/GEJ ca NO LIMIT, WJOG13320G @JCO_ASCO ➡️29 patients ➡️peritoneal met 44.8%, liver met 6.9% ✅ORR: 62.1%, CR: 10.3% ✅mPFS: 13.8 mo ✅mOS: NR, 12-month: 79.5% ❗️G3/4 TRAE: 37.9% 👉doi.org/10.1200/JCO-24-02463 @OncoAlert @ASCO #cancer #oncology #MedX #gastric
Image from Erman Akkus (@Erman_Akkus)
Image from Erman Akkus (@Erman_Akkus)
36
109
8,341
Gastric cancer - The Lancet Excellent review on multidisciplinary management of gastric cancer. Highly recommended for residents. A must-read!. ⁦@ACTEG_⁩ ⁦@mariglesiascoma⁩ ⁦⁩⁦@chierrocarbo⁩⁦@TamaraSN2⁩ ⁦@cpericay⁩ thelancet.com/journals/lance…
Gastric cancer

Gastric cancer

Gastric cancer remains a major health challenge worldwide, with nearly 1 million new cases annually contributing to more than 650 000 deaths. Epidemiologically, gastric cancer shows substantial...

thelancet.com
2
7
191
🙌🏻 moltes gràcies al Dr. @RobertMontal per la organització les ponències d'avui a la sessió YCEGC de la nostra @ACTEG_ felicitats a tots els ponents 🔥 📍Hospital Arnau de Vilanova, Lleida 🔛 seguim!
Image from Lucía Notario (@DrNotarioR)
2
6
190
el Dr. @EduardoTB94 del @VHIO ens fa un repàs molt interessant i actualitzat sobre el tractament actual del càncer gàstric MSI-H/dMMR 🔥🩺 ❓IO? IO-combo? QTP-IO? ❓seleccionem? TMB alt? T4? 👉🏻 consideracions clíniques! 📍 Hospital Arnau de Vilanova, Lleida @ACTEG_
Image from Lucía Notario (@DrNotarioR)
ACTEG (@ACTEG_) profile pictureACTEG@ACTEG_19 Mar 2025
4a Sessió de Young Catalan Esophago-Gastric Connection (YCEGC). 📅 Dimecres, 26 de març 🕠 Horari: 17:30 - 20:00 h 🧑🏻‍⚕️Robert Montal 📍 Lloc: Sala d’Actes, Hospital Universitari Arnau de Vilanova Us animem a participar per continuar amb la formació i el debat sobre temes d’interès.
Image from ACTEG (@ACTEG_)
2
8
475
🗓️El 10 de abril acercamos la investigación y estilos de vida a los pacientes con tumores esofagogastricos. Por y para ellos 🗓️💥@VHIO @vallhebron @ACTEG_ Inscripciones ⤵️
Vall d’Hebron Institute of Oncology (VHIO) (@VHIO) profile pictureVall d’Hebron Institute of Oncology (VHIO)
@VHIO22 Mar 2025
📣 Investigació del càncer d'estómac, esòfag i estils de vida saludables  💬 Amb @DanielAcostaEy1, @alcarazadriana_, Carolina Martínez, Sandra Castro, @EduardoTB94, @chierrocarbo , @MariaJosepCarre, @pgatell, Ramon Perisé, Jose Bau i Pilar Ruiz.   👉 linke.to/JornadaPacients_CEE…
Image from Vall d’Hebron Institute of Oncology (VHIO) (@VHIO)
4
1
8
1,201
Matterhorn ph3 trial POSITIVE for EFS in locally-LA EGC 🤩 Will it translate into increased OS? Maybe for PD-L1+ pts? 🆕 SOC? Feasible approval? How will it impact subsequent lines? Lots of questions on the table 🙇🏼 #UpperGI is 🔥 @VHIO @GrupoTTD @ACTEG_ @OncobitesTv
Image from Eduardo Terán (@EduardoTB94)
6
16
1,021
Fresh news! 🚨📰 A long-awaited study with an expected result—but highly needed 💥DESTINY-Gastrix04, TDXd in 2L HER2+ mGEA! Hope to be funded soon in Spain and globally 🌏 We need more agnostic and fast approvals! @GrupoTTD @ACTEG_
Kohei shitara (@KoheiShitara) profile pictureKohei shitara@KoheiShitara3 Mar 2025
DESTINY-Gastric04 demonstrated significantly prolonged OS with T-DXd vs. PTX+RAM in HER2+ gastric cancer. A major advancement for patients! Congratulations to all involved! @OncoAlert @oncodaily @DaiichiSankyoUS @AstraZeneca daiichisankyo.com/files/news…
3
9
835
Congrats for the #YCEGC 💥@PaulaCerd1 @HospitalSantPau @ACTEG_ First of the year 🚶
Image from Eduardo Terán (@EduardoTB94)
Image from Eduardo Terán (@EduardoTB94)
2
6
349
🟣“Future in locally advanced EG Cancer” Jornada de la Young Catalan Esophago-Gastric Connection (#YCEGC) @ACTEG_ organitzada a @HospitalSantPau per la Dra.Cerdà (@PaulaCerd1)
Image from OncoSantPau (@OncoSantPau)
4
9
399
ARMANI Trial 👨🏻‍🦱👩🏻‍🦰 Patients with GC/GEJ cancer. 🔬 Ramucirumab-paclitaxel as switch maintenance vs continuation FOLFOX in HER2-negative patients. ✅ mPFS: 6.6 vs 3.5 months ✅ mOS: 12.6 vs 10.4 months Should be an option for patients who are not eligible for IO.
Image from Ismael Macias Declara (@MaciasDeclara)
2
11
700
Load more